Inter Partes Review (IPR) Is Necessary to Lower Drug Prices by Ensuring that PTO Only Grants Patents that Reflect True Innovation
The problem remains: patients are paying too much for brand-name drugs.
Generic and biosimilar medicines are a proven solution to high drug prices and policies that continue to foster generic access are needed. Maintaining a strong and efficient IPR process is just one of those policies.
